ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Naproxen

Also written as “PN400”, “naproxen” and “Naproxen Sodium (Aleve, BAY117031)”.

Its studies are mostly in Pain · Osteoarthritis · Migraine Disorders · Osteoarthritis, Knee · Pain, Postoperative, led by 12 companies.

Drug pageNaproxen: every studyMany companies study it; this page follows only the 65 they lead. All 150 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 15, 201065 company-led studies, 1 open or runningNext primary completion: Oct 29, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayerits history only240 open or runningphase 4since Apr 15, 2010Jun 5, 2008none ahead
Pfizerits history only80 open or runningphase 4since Mar 28, 2008Aug 17, 2006none ahead
GlaxoSmithKlineits history only70 open or runningphase 4since Nov 17, 2008Oct 14, 2005none ahead
Aralez Pharmaceuticalsits history only60 open or runningphase 3since Aug 18, 2006Aug 18, 2006none ahead
Johnson & Johnsonits history only50 open or runningphase 4since Dec 2, 2005Dec 2, 2005none ahead
Dr. Reddy's Laboratoriesits history only40 open or runningphase 1since Jan 8, 2010Jan 8, 2010none ahead
Merckits history only40 open or runningphase 4since Sep 7, 2005Sep 7, 2005none ahead
Ache Laboratorios Farmaceuticosits history only20 open or runningphase 3since Jul 7, 2011Jul 7, 2011none ahead
Perrigoits history only20 open or runningphase 1since Dec 5, 2008Dec 5, 2008none ahead
Amgenits history only10 open or runningphase 2since Oct 19, 2012Oct 19, 2012none ahead
Kenvue Brands11 open or runningphase 3since Oct 15, 2026Oct 15, 2026Oct 29, 2027phase 3 · NCT07948811

Also a collaborator on its studies: Teva Pharmaceutical Industries and Pegus Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Kenvue Brands only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 15, 2026First study: phase 3 study in FeverFirst studyNCT07948811 · 292 planned · United States

Ahead

  1. Oct 29, 2027Primary completion: phase 3 study in FeverNCT07948811

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4137
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

The one study Kenvue Brands leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07948811Fever · United States3RecruitingOct 29, 2027292

How it is read

Names in the registry

  • “Naproxen”, 17 entries
  • “PN400”, 8 entries
  • “naproxen”, 5 entries
  • “Naproxen Sodium (Aleve, BAY117031)”, 4 entries
  • “Naproxen Sodium ER (BAYH6689)”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.